KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) Shares Outstanding (Weighted Average) (2016 - 2026)

Astrazeneca has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $2.0 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 5.85% year-over-year to $2.0 million; the TTM value through Mar 2026 reached $2.0 million, up 5.85%, while the annual FY2025 figure was $388.0 million, 0.0% changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $2.0 million at Astrazeneca, down from $388.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $1.6 billion in Q2 2023 and troughed at $250000.0 in Q1 2022.
  • A 5-year average of $410.7 million and a median of $388.0 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 154700.0% in 2023 and fell as far as 99.77% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $387.0 million in 2022, then grew by 0.26% to $388.0 million in 2023, then changed by 0.0% to $388.0 million in 2024, then changed by 0.0% to $388.0 million in 2025, then crashed by 99.49% to $2.0 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AZN at $2.0 million in Q1 2026, $388.0 million in Q4 2025, and $388.0 million in Q3 2025.